Shares of Neurocrine Biosciences Inc. sank to a new 52-week low Monday after one analyst said the stock was overpriced despite being off more than 75 percent so far this year. Neurocrine shares fell $1.11, or 7.3 percent, to $14.05 in morning trading on the Nasdaq, and reached a new 52-week low of $13.75 earlier in the session.
The Houston Chronicle